Objective. We hypothesized that multi-disciplinary assessment of patients with interstitial lung disease (ILD) would lead to improved diagnosis and management.
Introduction
Interstitial lung disease (ILD) represents a heterogeneous group of parenchymal lung disorders with common clinical manifestations. ILD is associated with significant morbidity and mortality and poses challenges in accurate diagnosis and treatment [1] . Distinguishing between ILD due to idiopathic pulmonary fibrosis (IPF) and ILD secondary to a rheumatic or CTD (CTD-ILD) is important, as the treatment and prognosis differ. IPF generally carries a poor prognosis with a 5-year survival <20%, whereas CTD-ILD has a variable, more favourable prognosis [2] .
Although multi-disciplinary management of chronic diseases streamlines costs and improves quality of care, this concept has not been examined in the ILD community. We hypothesized that the multi-disciplinary assessment of ILD patients referred to a tertiary care practice would lead to a more accurate diagnosis, and consequently alterations in treatment regimens that may lead to improved outcomes.
Patients and methods
Fifty patients were referred to the multi-disciplinary ILD clinic at Brigham and Women's Hospital (BWH) over a 12-month period for initial diagnostic and management recommendations. Data were collected at the time of visit and analysed retrospectively.
Initial assessment consisted of independent evaluations by both a pulmonologist and rheumatologist, including a detailed history, occupational and environmental exposures, medication history, family history and review of systems focusing on the skin, mucus membranes, musculoskeletal, oropharyngeal and gastrointestinal systems. A complete physical examination, including nail-fold capillaroscopy, was performed for each patient. Abnormal capillary microscopy was classified as either the presence of capillary haemorrhages, enlarged or giant capillaries, or disorganization of the normal capillary architecture. The clinic physicians reviewed all laboratory data, including anti-nuclear antibody (performed using HEp2 cell lines at BWH), ENAs, RF, inflammatory markers (ESR and CRP) and pulmonary function tests (PFTs). Imaging studies including high-resolution CT (HRCT) of the chest and pathology (lung biopsy if available) were independently reviewed by a radiologist and pathologist experienced in ILD. Additional studies such as an echocardiogram, oesophageal testing for pH or manometric studies, additional serological testing (i.e. anti-synthetase antibodies) or biopsies were performed at the discretion of the clinic practitioners. At the completion of the comprehensive assessment, a collaborative diagnostic and therapeutic management plan was developed.
CTD-ILD was diagnosed if ILD was found in the presence of rheumatic disease. A diagnosis for RA [3] , SLE [4] and WG was based on the ACR criteria. The LeRoy and Medsger [5] criteria were used to classify SSc. SS was diagnosed using the American-European criteria [6] . DM and PM were diagnosed with the Bohan-Peter criteria [7] . Patients were diagnosed with a UCTD if they had evidence of polyarthritis not fulfilling ACR criteria or RP or non-specific manifestations that did not meet ACR criteria for a specific rheumatic disease [8] . MCTD was diagnosed based on the Alarcon-Segovia criteria [9] . A diagnosis of anti-synthetase syndrome was considered if patients had constitutional symptoms, RP, mechanic's hands, arthritis, ILD and the presence of anti-synthetase antibodies [10] . IPF was diagnosed based upon American Thoracic Society/European Respiratory Society consensus guidelines in the absence of rheumatic disease [11] . The study was approved by the Institutional Review Board at BWH.
Statistical analysis
All continuous variables are reported as median (inter-quartile range). All categorical variables are reported as number (%). Continuous variables were compared using the Wilcoxon rank-sum testing method. Categorical variables were compared using chi-square analysis. A P 4 0.05 was considered to be statistically significant. All statistical assessments were performed using the SAS version 9 software.
Results
We evaluated 50 patients (27 women, 23 men) with a median age of 64 years (range 32-80 years). Thirty-eight patients had a history of smoking and 25 patients had >20 pack-years tobacco use, of which 11 had CTD-ILD and 7 had IPF. The median age of patients diagnosed with CTD-ILD was 65 years (range 54-70 years) and of IPF patients was 71 years (range 63-77 years). More patients with CTD-ILD were females than those with IPF or other lung diseases (P = 0.02).
Mean duration of ILD symptoms at the initial clinic visit was 33.4 months for IPF patients and 30.3 months for CTD-ILD patients. Mean duration of rheumatic symptoms such as RP or arthralgias in the CTD-ILD group was 42.5 months. On capillary microscopy, 6 patients with CTD-ILD had disorganized capillary loops, and another 12 patients had enlarged or giant capillary loops. One patient with IPF had enlarged capillary loops.
All patients with UCTD, MCTD, SSc, DM, SLE and SS had an ANA titre >1 : 160. One patient with IPF had an ANA 1 : 40. All three patients with anti-synthetase syndrome had positive antibodies, two with PL-12 antibody and one with Jo-1 antibody. Both patients with MCTD had a positive RNP. All DM patients had an elevated creatinine kinase (CK). One patient with WG had a positive cANCA pattern with antibodies against proteinase 3. All five RA patients were RF positive.
There were no differences in PFTs among the CTD-ILD and IPF groups, including forced vital capacity (FVC) and diffusing capacity for carbon monoxide (DL CO ). Five patients with CTD-ILD and seven patients with IPF had changes consistent with usual interstitial pneumonia (UIP) on HRCT. Of these patients, four with CTD-ILD and four with IPF had confirmatory histopathology consistent with UIP. Non-specific interstitial pneumonia (NSIP) was noted in seven patients with CTD-ILD and none in IPF ( Table 1) . The remainder of patients with CTD-ILD had either a mixed pattern on HRCT (denoted as 'other' in Table 2 ) or lymphocytic interstitial pneumonia (LIP). In total, 20 patients had a lung biopsy and 10 (50%) of these patients had a change in diagnosis or treatment after lung biopsy, of which changes in 3 patients were based solely on biopsy.
The final diagnosis in all patients referred to the ILD clinic included 25 patients with CTD-ILD, 15 patients with IPF and 10 patients with other lung diseases (including cryptogenic organizing pneumonia, druginduced ILD and vasculitis). Among the 25 patients with a final diagnosis of CTD-ILD, 7 were referred with an initial diagnosis of IPF (Table 2) . Nine patients with an initial diagnosis of CTD-ILD had their diagnosis changed to an alternate CTD-ILD after evaluation in clinic. The final diagnoses in the CTD-ILD group included five patients each with UCTD and RA, respectively, three patients each with a diagnosis of SSc, DM and anti-synthetase syndrome, respectively, two patients each with MCTD and SS and one patient each with a diagnosis of SLE and WG, respectively. Of the 10 patients with a final diagnosis of other lung disease, the referring diagnosis was changed in 8 patients after evaluation in our ILD clinic. Therapy was changed in 20 of 25 patients with CTD-ILD ( Table 2 ) and in 4 of 15 patients with IPF. The majority of patients with a CTD-ILD had their regimens switched to a combination of CSs with an immunomodulatory agent. Two patients with SS were treated with rituximab. Four of five patients with RA had no change in treatment.
Discussion
In our cohort, 50% of patients were diagnosed with CTD-ILD, a much higher percentage than previously reported [12] . Although this may reflect the referral patterns of a tertiary centre, it also suggests that previous studies may underestimate CTD-ILD, as the clinical features of rheumatic disease can be subtle and difficult to diagnose. Our patients with CTD-ILD in fact had rheumatic symptoms for a mean duration of 42.5 months before clinic evaluation. In addition, as lung involvement can precede rheumatic manifestations, a rheumatic diagnosis at initial visit may also be difficult. The unique aspect of a Impact of rheumatological evaluation in interstitial lung disease patients multi-disciplinary clinic is the concurrent evaluation of ILD patients by a pulmonologist and rheumatologist, utilizing a collaborative approach to evaluate, manage and potentially affect disease outcomes. Certain types of ILD are associated with better prognoses and may be more amenable to treatment. A retrospective analysis evaluating 362 ILD patients, of whom 269 had IPF and 93 had CTD-ILD, showed that CTD-ILD was associated with a better survival at 5 years than IPF [2] . This finding may be related to histopathology of CTD-ILD, which in most cases is NSIP, and less frequently UIP. IPF usually has a worse prognosis and is least responsive to therapy. As a result, differentiation of IPF from CTD-ILD is essential for prognosis and consideration for therapy, including consideration for lung transplantation.
Accurate evaluation of patients with ILD is critical, as previous data suggest significant variation in the diagnosis of ILD among physicians. In a retrospective review of 39 ILD cases, comparing academic vs community evaluation, community physicians were more likely to assign a diagnosis of IPF than academic physicians, and the rate of agreement among academic physicians was higher than community physicians [13, 14] . In our study, a significant number of patients who presented with a diagnosis of IPF had their diagnosis altered after evaluation. In addition, subtle findings on rheumatological evaluation (nail-fold capillary microscopy, evidence of mechanic's hands) or additional serologies obtained at the visit frequently changed or further defined the diagnosis. In our study, the majority of patients with CTD-ILD had nail-fold capillary changes, whereas only one patient with IPF had capillary changes.
The pathological findings noted in our study were consistent with previous studies [15, 16] . The predominant histopathological pattern in the CTD-ILD group was NSIP, whereas UIP was the predominant pattern in patients with IPF. Four of five patients with RA-ILD, however, had a UIP pattern, which is reported to be a more common pattern in RA-ILD than the NSIP pattern [16] . Patients with IPF can also have NSIP on histopathology, though none was noted in our cohort. A recent study evaluating patients with idiopathic NSIP suggests that a significant proportion of these patients may evolve to a UCTD [15] ; therefore, long-term follow-up of these patients will prove to be important. Lung biopsy was performed in 20 of our patients and among those 10 had a change in diagnosis after biopsy with 3 of those patients having a change in diagnosis or treatment based solely on lung biopsy.
The majority of our patients with CTD-ILD (80%) had a change in therapy. Often this change was based on histologic pattern and a final clinical diagnosis. In those patients with NSIP, often CSs and an immunomodulatory agent were added. In our patients with RA, no change in therapy was made as these patients were already on appropriate regimens for their RA [17] . At this time, it is not clear what these treatment options necessarily mean for the patient; therefore, long-term follow-up will be important.
Our findings are limited by the retrospective analysis of patients and the small size of our patient cohort. In addition, our patients with CTD-ILD were older at the initial clinic visit than the average patient with rheumatic disease, which may be due to a referral bias and also time of patient presentation. A majority of our patients also had a smoking history and while IPF and RA-ILD are more prevalent in smokers [18, 19] it is unclear how much of a role tobacco use had in our patients with CTD-ILD. Lastly, HRCT was often used to suggest pathology (when biopsy was not available), a reliable indicator of underlying pathology in many but certainly not all cases [20] .
In summary, the correct classification of ILD is important with regards to epidemiology, consideration for lung transplantation and enrolment in clinical trials. Differentiating between IPF and CTD-ILD substantially impacts upon treatment and may impact prognosis. A multi-disciplinary clinic offers an innovative approach in evaluating patients with ILD. A diagnosis of CTD-ILD may lead to additional immunomodulatory therapy, whereas a diagnosis of IPF may lead to discontinuation of immunosuppressive therapy, thereby preventing substantial treatment-related side effects. In addition, this approach allows for a thorough evaluation of concomitant complications including aspiration, pulmonary hypertension, and necessary immunizations and prophylaxis. Although further study is needed to define the impact of this approach on patient survival, satisfaction and the cost of care, we would advocate a multi-disciplinary approach to the evaluation of patients with ILD, where the rheumatologist plays a central role in the evaluation and care of these patients.
Rheumatology key messages
. A multi-disciplinary ILD clinic enhances diagnosis and management of patients with ILD. . Rheumatologists by eliciting subtle clues are integral to the care of patients with ILD. 
